241 related articles for article (PubMed ID: 12853352)
21. A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer.
Bennouna J; Monnier A; Rivière A; Milleron B; Lemarie E; Trillet-Lenoir V; Soussan-Lazard K; Berille J; Douillard JY
Eur J Cancer; 2000 Jun; 36(9):1107-12. PubMed ID: 10854943
[TBL] [Abstract][Full Text] [Related]
22. First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
Kourousis C; Androulakis N; Kakolyris S; Souglakos J; Maltezakis G; Metaxaris G; Chalkiadakis G; Samonis G; Vlachonikolis J; Georgoulias V
Cancer; 1998 Nov; 83(10):2083-90. PubMed ID: 9827712
[TBL] [Abstract][Full Text] [Related]
23. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
25. Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma.
Katsaros D; Oletti MV; Rigault de la Longrais IA; Ferrero A; Celano A; Fracchioli S; Donadio M; Passera R; Cattel L; Bumma C
Ann Oncol; 2005 Feb; 16(2):300-6. PubMed ID: 15668288
[TBL] [Abstract][Full Text] [Related]
26. Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.
Song SY; Kim WS; Kim K; Jung CW; Im YH; Kim HJ; Kang WK; Lee HG; Kwon OJ; Rhee CH; Park CH; Park K
Jpn J Clin Oncol; 2003 Oct; 33(10):509-13. PubMed ID: 14623918
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
Michelotti A; Gennari A; Salvadori B; Giannessi PG; Baldini E; Tibaldi C; Da Prato M; Conte PF
Semin Oncol; 1996 Oct; 23(5 Suppl 11):38-40. PubMed ID: 8893898
[TBL] [Abstract][Full Text] [Related]
28. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.
Douillard JY; Gervais R; Dabouis G; Le Groumellec A; D'Arlhac M; Spaeth D; Coudert B; Caillaud D; Monnier A; Clary C; Maury B; Mornet M; Rivière A; Clouet P; Couteau C
Ann Oncol; 2005 Jan; 16(1):81-9. PubMed ID: 15598943
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma.
Airoldi M; Cortesina G; Giordano C; Pedani F; Bumma C; Gabriele P
Med Oncol; 2003; 20(1):19-24. PubMed ID: 12665680
[TBL] [Abstract][Full Text] [Related]
30. Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
Campone M; Fumoleau P; Delecroix V; Deporte-Fety R; Perrocheau G; Vernillet L; Borg-Olivier O; Louboutin JP; Bissery MC; Riva A; Azli N
Ann Oncol; 2001 Jul; 12(7):909-18. PubMed ID: 11521794
[TBL] [Abstract][Full Text] [Related]
31. Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.
Esteban E; Modollel A; González de Sande L; Palacio I; Muñiz I; Fernández Y; Corral N; Fra J; Sala M; Vieitez JM; Estrada E; Lacave AJ;
Breast Cancer Res Treat; 2003 Aug; 80(3):257-65. PubMed ID: 14503798
[TBL] [Abstract][Full Text] [Related]
32. A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer.
Masters GA; Mauer AM; Hoffman PC; Wyka D; Samuels BL; Krauss SA; Watson S; Golomb H; Vokes EE
Ann Oncol; 1998 Jun; 9(6):677-80. PubMed ID: 9681085
[TBL] [Abstract][Full Text] [Related]
33. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
34. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
Ferraresi V; Milella M; Vaccaro A; D'Ottavio AM; Papaldo P; Nisticò C; Thorel MF; Marsella A; Carpino A; Giannarelli D; Terzoli E; Cognetti F
Am J Clin Oncol; 2000 Apr; 23(2):132-9. PubMed ID: 10776972
[TBL] [Abstract][Full Text] [Related]
35. Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.
Feliu J; Martin G; Lizón J; Chacón JI; Dorta J; de Castro J; Rodríguez A; Sánchez Heras B; Torrego JC; Espinosa E; González Barón M;
Ann Oncol; 2001 Oct; 12(10):1369-74. PubMed ID: 11762806
[TBL] [Abstract][Full Text] [Related]
36. Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines.
Martí JL; Bueso P; Mayordomo JI; Isla MD; Saenz A; Escudero P; Murillo L; Filipovich E; Andres R; Tres A
Ann Oncol; 2001 Aug; 12(8):1061-5. PubMed ID: 11583186
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
Specht L; Larsen SK; Hansen HS
Ann Oncol; 2000 Jul; 11(7):845-9. PubMed ID: 10997812
[TBL] [Abstract][Full Text] [Related]
38. Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
Koinis F; Polyzos A; Christopoulou A; Zafeiriou Z; Emmanouilidis C; Papadimitraki E; Kalykaki A; Kalbakis K; Samonis G; Georgoulias V
Cancer Chemother Pharmacol; 2014 Apr; 73(4):819-25. PubMed ID: 24531559
[TBL] [Abstract][Full Text] [Related]
39. Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02).
Vázquez S; Huidobro G; Amenedo M; Fírvida JL; León L; Lázaro M; Grande C; Mel JR; Ramos M; Salgado M; Casal J
Anticancer Drugs; 2007 Nov; 18(10):1201-6. PubMed ID: 17893521
[TBL] [Abstract][Full Text] [Related]
40. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]